TrumpRx: White House rolls out cash-pay drug hub to lower costs

The White House announced TrumpRx, a direct-to-consumer hub that directs cash-paying patients to discounts offered by drugmakers on their own sites, as part of efforts to lower U.S. prescription costs. The site does not sell drugs itself and may not benefit insured patients who rely on coverage, but could help uninsured or underinsured access drugs not widely covered, such as obesity medications; participating makers include Lilly and Novo Nordisk, with prices advertised (e.g., Ozempic and Wegovy at about $350/month) amid broader debated savings, since actual prices often depend on rebates and payer contracts. The overall impact on out-of-pocket costs remains uncertain.